Felcorekibart for chronic obstructive pulmonary disease (COPD)
Part of Lungs & breathing clinical trials.
This study tests a new medicine, felcorekibart, to see if it can reduce COPD flare-ups better than a placebo after 52 weeks. It's designed for people with high eosinophils, a type of white blood cell linked to inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 40 to 80 years old
- Have moderate to severe COPD with frequent flare-ups
- Have high blood levels of eosinophils, a type of white blood cell
- Currently use inhaled COPD treatments, like triple therapy or dual inhalers, if appropriate
- Be a current or former smoker
- Not have asthma or other significant lung disease
- Not have had a recent heart attack, stroke, or heart failure
- Not have used oxygen therapy for more than 16 hours a day
- Not have had cancer in the last 5 years (except for treated skin cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication (GSK5784283) for people with moderate to severe COPD who have a certain type of inflammation (eosinophilic). Participants must be on standard inhaler therapy and have a history of smoking. The trial will compare the new drug to a placebo.
This study tests an inhaled medication called ensifentrine to see if it can prevent flare-ups (exacerbations) in people with COPD who have had at least one moderate or severe flare-up in the past year while on their current treatment. If you qualify, you may receive the study drug or a placebo, and your COPD symptoms and flare-ups will be closely monitored.
This trial tests an investigational drug called Rademikibart for people having a severe asthma or COPD flare-up that needs emergency care and steroids. The study aims to see if the drug can help control the flare-up faster and reduce the need for more treatment.
This trial tests a new medicine called PF-07275315 for people with moderate to severe COPD. It aims to see if it can help reduce flare-ups (sudden worsening of symptoms) when added to your usual treatment.
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
This study tests an experimental medication called felcorekibart, given as an injection, to see if it reduces nasal polyps and improves sinus symptoms like congestion and loss of smell. It is for adults who have had nasal polyps for at least a year and have already tried standard treatments like steroid sprays or pills, or had surgery.
Hear when a new Pulmonary Disease, Chronic Obstructive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.